Royce & Associates LP Decreases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Royce & Associates LP decreased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 6.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,021,105 shares of the biopharmaceutical company’s stock after selling 140,917 shares during the period. Royce & Associates LP owned about 1.70% of Catalyst Pharmaceuticals worth $40,180,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of CPRX. GAMMA Investing LLC lifted its position in shares of Catalyst Pharmaceuticals by 62.1% during the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Catalyst Pharmaceuticals during the third quarter worth about $50,000. CWM LLC lifted its position in shares of Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Catalyst Pharmaceuticals during the second quarter worth about $70,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Catalyst Pharmaceuticals during the second quarter worth about $153,000. Institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now owns 348,874 shares in the company, valued at $7,012,367.40. This trade represents a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Steve Miller sold 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the sale, the insider now directly owns 675,124 shares in the company, valued at approximately $13,738,773.40. The trade was a 18.18 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Citigroup increased their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $30.50.

Catalyst Pharmaceuticals Trading Down 4.9 %

Shares of NASDAQ:CPRX opened at $21.69 on Friday. The firm’s 50 day moving average is $20.97 and its two-hundred day moving average is $18.28. Catalyst Pharmaceuticals, Inc. has a 52 week low of $13.00 and a 52 week high of $24.27. The firm has a market capitalization of $2.59 billion, a P/E ratio of 18.38, a PEG ratio of 3.51 and a beta of 0.75.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.